ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 152 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2015. The put-call ratio across all filers is 1.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,640,517 | -4.6% | 1,027,785 | +23.4% | 0.00% | 0.0% |
| Q2 2023 | $38,411,367 | -52.3% | 832,677 | -58.5% | 0.00% | -25.0% |
| Q1 2023 | $80,522,686 | +61.1% | 2,008,048 | +86.1% | 0.00% | -20.0% |
| Q4 2022 | $49,993,474 | +23.2% | 1,079,074 | +10.1% | 0.01% | +25.0% |
| Q3 2022 | $40,572,000 | -41.3% | 979,779 | -15.4% | 0.00% | -42.9% |
| Q2 2022 | $69,102,000 | -24.2% | 1,158,242 | -7.7% | 0.01% | 0.0% |
| Q1 2022 | $91,177,000 | -16.0% | 1,255,524 | -2.8% | 0.01% | -12.5% |
| Q4 2021 | $108,592,000 | +3.7% | 1,291,379 | +11.2% | 0.01% | 0.0% |
| Q3 2021 | $104,709,000 | +25.6% | 1,160,985 | +32.7% | 0.01% | +14.3% |
| Q2 2021 | $83,395,000 | -16.5% | 874,614 | -0.3% | 0.01% | -22.2% |
| Q1 2021 | $99,914,000 | -32.6% | 877,514 | -18.1% | 0.01% | -30.8% |
| Q4 2020 | $148,327,000 | +54.2% | 1,071,499 | -8.4% | 0.01% | +30.0% |
| Q3 2020 | $96,171,000 | -14.7% | 1,170,099 | -18.9% | 0.01% | -16.7% |
| Q2 2020 | $112,801,000 | +43.0% | 1,442,102 | -18.8% | 0.01% | +9.1% |
| Q1 2020 | $78,895,000 | +1.3% | 1,775,710 | -2.6% | 0.01% | +22.2% |
| Q4 2019 | $77,876,000 | -12.6% | 1,823,374 | -12.5% | 0.01% | -18.2% |
| Q3 2019 | $89,137,000 | -38.7% | 2,083,621 | -9.1% | 0.01% | -35.3% |
| Q2 2019 | $145,497,000 | -16.7% | 2,291,288 | -9.0% | 0.02% | -19.0% |
| Q1 2019 | $174,630,000 | +36.3% | 2,517,746 | -14.6% | 0.02% | +16.7% |
| Q4 2018 | $128,133,000 | -49.6% | 2,946,924 | -11.4% | 0.02% | -37.9% |
| Q3 2018 | $254,011,000 | -4.5% | 3,327,381 | -3.8% | 0.03% | -6.5% |
| Q2 2018 | $265,899,000 | +32.2% | 3,459,085 | -12.3% | 0.03% | +29.2% |
| Q1 2018 | $201,154,000 | +19.1% | 3,944,982 | +8.3% | 0.02% | +20.0% |
| Q4 2017 | $168,912,000 | -13.3% | 3,641,921 | -0.4% | 0.02% | -16.7% |
| Q3 2017 | $194,783,000 | -17.6% | 3,657,208 | -3.9% | 0.02% | -17.2% |
| Q2 2017 | $236,280,000 | -43.0% | 3,804,225 | -37.7% | 0.03% | -45.3% |
| Q1 2017 | $414,178,000 | +0.1% | 6,110,627 | +3.9% | 0.05% | -3.6% |
| Q4 2016 | $413,622,000 | -1.4% | 5,882,825 | -0.5% | 0.06% | -1.8% |
| Q3 2016 | $419,474,000 | +46.7% | 5,913,075 | +1.1% | 0.06% | +43.6% |
| Q2 2016 | $286,015,000 | -22.7% | 5,847,783 | +0.1% | 0.04% | -23.5% |
| Q1 2016 | $369,834,000 | -43.4% | 5,841,631 | +0.3% | 0.05% | -42.0% |
| Q4 2015 | $653,217,000 | +16.9% | 5,822,942 | +0.4% | 0.09% | +10.0% |
| Q3 2015 | $558,598,000 | +1.4% | 5,799,996 | +7.8% | 0.08% | +12.7% |
| Q2 2015 | $550,943,000 | +66.4% | 5,380,827 | +0.9% | 0.07% | +69.0% |
| Q1 2015 | $331,112,000 | +57.8% | 5,332,783 | +11.5% | 0.04% | +55.6% |
| Q4 2014 | $209,809,000 | -19.3% | 4,781,420 | +4.1% | 0.03% | -22.9% |
| Q3 2014 | $260,034,000 | +108.8% | 4,594,240 | +1.9% | 0.04% | +105.9% |
| Q2 2014 | $124,517,000 | +46.3% | 4,508,893 | +25.2% | 0.02% | +41.7% |
| Q1 2014 | $85,100,000 | – | 3,600,488 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |